Enhancing Immunity Using Chimeric CD40 Ligand and Coronavirus Vaccine
AssigneeMEMGen Corporation
InventorMark J. CANTWELL
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and compositions for enhancing immunity by administering a coronavirus vaccine and a chimeric CD40L polypeptide. The coronavirus vaccine can be comprised of inactivated coronaviral particles or an antigenic polypeptide, preferably the coronavirus spike protein. The coronavirus antigenic polypeptide can be a purified antigenic polypeptide or a nucleic acid expression construct that encodes the antigenic polypeptide. The chimeric CD40L polypeptide in compositions of the invention can be a purified chimeric CD40L polypeptide or a nucleic acid expression construction that encodes the chimeric CD40L polypeptide.
Claims43
A composition comprising:
- a coronavirus vaccine;
- and
- at least one of a chimeric CD40L polypeptide or a nucleic acid encoding a chimeric CD40L polypeptide.
A method of enhancing immunity comprising:
- administering a pharmaceutical formulation comprising a coronavirus vaccine;
- and
- administering a pharmaceutical formulation comprising at least one of a chimeric CD40L polypeptide or a nucleic acid encoding a chimeric CD40L polypeptide.
A method of enhancing immunity comprising:
- admixing a pharmaceutical formulation comprising a coronavirus vaccine with a pharmaceutical formulation comprising at least one of a chimeric CD40L polypeptide or a nucleic acid encoding a chimeric CD40L polypeptide;
- administering the admixed formulations to a person or animal.
A method of enhancing immunity comprising:
- administering a pharmaceutical formulation comprising a coronavirus vaccine and one of:
- a chimeric CD40L polypeptide or a nucleic acid construct encoding a chimeric CD40L polypeptide.
A kit for administration to a person or animal comprising:
- a pharmaceutical formulation comprising a coronavirus vaccine;
- and
- a pharmaceutical formulation comprising at least one of a chimeric CD40L polypeptide or a nucleic acid encoding a chimeric CD40L polypeptide.
A composition comprising:
- a pharmaceutical formulation of a coronavirus vaccine;
- and
- a pharmaceutical formulation of at least one of a chimeric CD40L polypeptide or a nucleic acid encoding a chimeric CD40L polypeptide.
Dependencies are inferred from the claim text.